Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Autor: Andre, T., Amonkar, M., Norquist, J., Shiu, K-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J., Smith, D., Garcia-Carbonero, R., Sevilla, I., de la Fouchardiere, C., Rivera, F., Elez, E., Diaz, L. A., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., Le, D.

Publikováno v: Andre, T, Amonkar, M, Norquist, J, Shiu, K-K, Kim, T W, Jensen, B V, Jensen, L H, Punt, C J, Smith, D, Garcia-Carbonero, R, Sevilla, I, de la Fouchardiere, C, Rivera, F, Elez, E, Diaz, L A, Yoshino, T, Van Cutsem, E, Yang, P, Farooqui, M Z H & Le, D 2020, ' Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study ', Annals of Oncology, vol. 31, no. Suppl. 4, 396O, pp. S409 . https://doi.org/10.1016/j.annonc.2020.08.507

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::126e6671a1fb707217b0d8b7ff684515
https://portal.findresearcher.sdu.dk/da/publications/303a4508-aadd-475e-81c2-01fb33425dd3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Direct in vivoevidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Autor: Herndon, T M, Chen, S-S, Saba, N S, Valdez, J, Emson, C, Gatmaitan, M, Tian, X, Hughes, T E, Sun, C, Arthur, D C, Stetler-Stevenson, M, Yuan, C M, Niemann, C U, Marti, G E, Aue, G, Soto, S, Farooqui, M Z H, Herman, S E M, Chiorazzi, N, Wiestner, A

Publikováno v: Leukemia; June 2017, Vol. 31 Issue: 6 p1340-1347, 8p